U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661459) titled 'Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)' on June 16.
Brief Summary: This study evaluates whether optimization of ancillary therapies can improve the efficacy of immune checkpoint therapy in participants with solid tumors. The ancillary therapies being optimized include the avoidance of daily acetaminophen and cannabis/THC/CBD while prescribing aspirin and loratadine. The goal is to see if optimizing these four drugs can improve the efficacy of the treatment compared to a matched historical control.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumors...